In the ever-evolving landscape of pharmaceutical innovation, Unibest is proud to announce a groundbreaking development in the administration of Semaglutide, codenamed UB-PEP-104.
READ MOREThe transcription factor c-Myc has emerged as a critical target in oncology, given its aberrant expression in more than 70% of human cancers. Unibest presents a first-in-class small molecule glue targeting c-Myc open for NewCo.
READ MOREWe, Unibest, are excited to share with you the remarkable benefits and opportunities that Reteplase brings to the global market.
READ MOREUnibest is proud to partner with a renowned Chinese Pharmaceutical company and announce the following global licensing opportunities:1.
READ MOREThrombolytic drugs play a crucial role in treating various venous and arterial thromboembolic conditions, particularly acute myocardial infarction.
READ MOREHeparin is one of the oldest biological drugs used in treating thrombosis and hemostasis. It is a naturally occurring polysaccharide in the glycosaminoglycan (GAG) family, found primarily in mast cells.
READ MOREWith the development of chemotherapy agents, we've witnessed remarkable strides in the development of chemotherapy agents, resulting in improved efficacy and reduced side effects. However, a critical challenge persists that demands our attention: the management of chemotherapy-induced thrombocytopenia.
READ MORE